[CAS NO. 1787294-07-8] Remibrutinib (LOU064)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1787294-07-8]
Store
Catalog
SLK-S9660
Brand
Selleck
CAS
1787294-07-8
DESCRIPTION [1787294-07-8]
Overview
| MDL | MFCD32215329 |
|---|---|
| Molecular Weight | 507.53 |
| Molecular Formula | C27H27F2N5O3 |
| SMILES | - |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9703 mL | 9.8516 mL | 19.7033 mL |
| 5 mM | 0.3941 mL | 1.9703 mL | 3.9407 mL |
| 10 mM | 0.1970 mL | 0.9852 mL | 1.9703 mL |
| 50 mM | 0.0394 mL | 0.1970 mL | 0.3941 mL |
Description
Remibrutinib (LOU064) is a potent, highly selective covalent inhibitor of with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases.
In vitro
LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.